Analysts at Mizuho have named their top pick for 2024 in the pharma sector, saying there is still sizeable upside ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE